DEEP VEIN THROMBOSIS AND RECURENT PULMONARY EMBOLISM IN A PATIENT WITH THROMBOPHILIC MUTATIONS AND GENERALIZED PSORIASIS: A CASE REPORT
Introduction: Genetic risk factors that increase venous thromboembolism risk are disorders in the synthesis or activity of coagulation factors. Factor V Leiden, prothrombin (20210-A), antithrombin deficiency, protein C and protein S deficiency, and hyperhomocysteinaemia are the most common venous thromboembolism-related gene mutations. When genetic factors are combined with non-provoking risk factors (obesity, psoriasis, smoking and previous venous thromboembolism) the result is increased venous thromboembolism risk for each factor individually. Previous venous thromboembolism is one of the strongest risk factors, even in patients actively treated with anticoagulant. Patients are more likely to have recurrent venous thromboembolism with longer duration. Psoriasis is a complex immune–mediated disease, associated with cardiovascular risk, hypercoagulability markers and elevated homocysteine. Lots of observational reports suggest increased incidence of venous trombembolic events in patient with psoriasis.
Case presentation: We present patient with inherited thrombophilia and chronic diffuse plaque psoriasis complicated with deep venous thrombosis and pulmonary embolism. DNA analysis indicates the presence of homozygosis for Factor V Leiden mutation as well as heterozygosis for Factor XIII V34L, PAI -1 5G/4G and MTHFR A1298C polymorphism. Dermatological anamnesis is positive for plaque psoriasis since 12 years ago.
Conclusion: The presentation of this case indicates an association between venous thromboembolism and chronic psoriasis. All patients with recurrent thromboembolism, hereditary thrombophilia, and moderate to severe psoriasis should be considered to be at higher risk for venous thromboembolism and appropriately treated.
Fox EA, Kahn SR: The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost. 2005; 94(2):362-5.
Ogdie A, Kay McGill N, Shin DB, Takeshita J , Love TJ, Noe MH et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J. 2018;39(39):3608-14.
Karabudak O, Ulusoy RE, Erikci AA, Solmazgul E, Dogan B, Harmanyeri Y. Inflammation and hypercoagulable state in adult psoriatic men. Acta Derm Venereol. 2008;88(4):337–40.
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol.2017;31(2):205-12.
Ahlehoff O, Gislason GH, Lindhardsen J, Charlot MG, Jorgensen CH, Olesen JB et al. Psoriasis carries an increased risk of venous thromboembolism: A danish nationwide cohort study. PloS one. 2011;6(3): e18125.
Heit J, Sobell J, Li H, Sommer SS. The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study. J Thromb Haemost. 2005;3(2):305–11.
Saemundsson Y, Sveinsdottir SV, Svantesson H, Svensson PJ. Homozygous Factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation. J Thromb Thrombolysis. 2013;36(3):324–31.
Bunch JL. Psoriasis associated with thrombosis of the Inferior Vena Cava. Proc R Soc Med. 1914;7:257–8.
Lutsey P, Prizment A, Folsom A. Psoriasis is associated with a greater risk of incident venous thromboembolism: the Iowa Women's Health Study. J Tromb Haemost. 2012;10(4):708-11.
Gisondi P, Malerba M, Malara G, Puglisi Guerra A, Sala R, Radaeli A, et al. C-reactive protein and markers for thrombophilia in patients with chronic plaque psoriasis. Int J Immunopathol Pharmacol. 2010;23(4):1195-202.
Hajjar KA, Mauri L, Jacovina AT, Zhong F, Mirza UA, Padovan JC et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem. 1998;273(16):9987–93.
Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Rodriguez L, Miranda-Filloy JA, Fernandez-Gutierrez B, et al. A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Res Ther. 2010;12(2):R71.
Zoller B, Garcia de Frutos P, Dahlback B. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency. Thromb Haemost. 1998;79(4):802–7.
- There are currently no refbacks.
Copyright (c) 2020 Marjan Nove Baloski, Daniela Buklioska Ilievska, Vesna Brishkovska-Boshkovski, Taner Hasan, Natasa Nedeska Minova, Biljana Prgova-Veljanova, Andrea Nanceva Boguchevska, Jasminka Nanceva, Marijan Bosevski, Sasho Panov
This work is licensed under a Creative Commons Attribution 4.0 International License.